Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | FLT4 | P35916 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | FRK | P42685 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.37 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.37 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.37 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362007 | 1.00 | PIM2 (0.46) | PIM2L3MBTL1LRRK2EGFRPRKD3 | |
| SCHEMBL1364351 | 0.86 | PIM2 (0.45) | PIM2L3MBTL1LRRK2EGFRFYN | |
| SCHEMBL857900 | 0.86 | PIM2 (0.45) | PIM2L3MBTL1LRRK2EGFRFYN | |
| SCHEMBL1362095 | 0.84 | PIM2 (0.47) | PIM2LRRK2 | |
| SCHEMBL856856 | 0.84 | PIM2 (0.47) | PIM2LRRK2 | |
| SCHEMBL1363653 | 0.84 | LRRK2 (0.50) | PIM2LRRK2PRKD3MAP4K4AXL | |
| SCHEMBL858239 | 0.84 | LRRK2 (0.50) | PIM2LRRK2PRKD3MAP4K4AXL | |
| SCHEMBL1364814 | 0.83 | PIM2 (0.44) | PIM2LRRK2EGFRMAP4K4CLK4 | |
| SCHEMBL857008 | 0.83 | PIM2 (0.44) | PIM2LRRK2EGFRMAP4K4CLK4 | |
| SCHEMBL857089 | 0.83 | PIM2 (0.46) | PIM2LRRK2EGFRPRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067434-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | claimed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | PIM2 2832/4885L3MBTL1 1678/4885LRRK2 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.